The Psychedelic Mental Health Access Alliance is a multi-state initiative developing the care models, partnerships, and evidence needed to bring psychedelic-assisted therapy (PAT) into Medicaid and other public systems. Our focus is simple: ensuring that people who depend on publicly funded mental health care can benefit from PAT as they become available.
For thousands of years, psychedelic medicines have been held with reverence, care, and responsibility within Indigenous and spiritual traditions that continue to steward these practices today. Long before clinical trials, communities around the world understood these medicines as tools for healing, insight, connection, and transformation.
Now, after decades of prohibition and a long pause in scientific inquiry, Western research is catching up. Hundreds of studies have begun to validate what many practitioners, healers, and communities have known through experience: when combined with skilled support, careful preparation, and integration, psychedelic-assisted therapies can help relieve profound forms of suffering and support lasting change.
We are living through a remarkable moment in the evolution of mental-health care. Long-held traditions, lived experience, and modern science are beginning to converge, creating new possibilities for how healing is understood, delivered, and sustained. The opportunity before us is not simply to advance new treatments, but to ensure the benefits of this emerging field can reach the people and communities who stand to benefit most.
The field is advancing rapidly, yet much of today’s research, infrastructure, and access pathways remain concentrated in academic and private-pay environments. Far less attention has been devoted to understanding how psychedelic-assisted therapy can be effectively delivered within public health systems and adapted to the needs of the communities they serve. PMHA Alliance exists to close that gap , through community-informed pilot studies, implementation tools, and culturally and clinically aligned care models designed for Medicaid populations.
State Medicaid agencies are responsible for delivering healthcare to millions of people while managing workforce shortages, rising behavioral-health needs, budget pressures, and shifting federal and state priorities. In this environment, even promising innovations like psychedelic-assisted therapy often struggle to gain traction, not because of a lack of interest, but because of limited capacity and competing demands.
For psychedelic-assisted therapy to become a broadly accessible benefit, not just covered on paper, but reachable in practice, Medicaid agencies need evidence that the treatment is safe, effective, cost-effective, and capable of expanding access to care. They also need real-world examples, implementation insights, and practical guidance to inform future policy and coverage decisions.
Medicaid sits at the front door of mental health care for millions of Americans. As breakthrough therapies begin moving from research into practice, public systems face an important question: how do promising innovations become real-world care? Psychedelic-assisted therapy offers tremendous potential, but realizing that potential at scale will require evidence, implementation models, and pathways designed for the realities of public healthcare.
PMHA Alliance generates the evidence, implementation learnings, stakeholder alignment, and practical tools needed to support the responsible integration of psychedelic-assisted therapy into publicly funded mental healthcare systems. Across 50 states, there is no single pathway to coverage. By helping build the infrastructure for adoption now, PMHA Alliance aims to shorten the distance between scientific promise and real-world access, so that people living with PTSD, treatment-resistant depression, and other serious mental health challenges are not left waiting decades for care.
Proof, pull, and policy, how PAT moves from boutique into the public health system.
Generate Medicaid-ready evidence
Multi-state pilots use group-based care for high-need Medicaid populations, generating the evidence policymakers need at publicly fundable costs.
Spread proof across states
When diverse states prove affordable PAT works, others follow, giving Medicaid directors the evidence they need to cover it.
Build reimbursement pathways
Public policy enabling PAT within publicly funded mental health systems, turning successful pilots into durable Medicaid coverage.
Generate Medicaid-ready evidence
Multi-state pilots use group-based care for high-need Medicaid populations, generating the evidence policymakers need at publicly fundable costs.
Spread proof across states
When diverse states prove affordable PAT works, others follow, giving Medicaid directors the evidence they need to cover it.
Build reimbursement pathways
Public policy enabling PAT within publicly funded mental health systems, turning successful pilots into durable Medicaid coverage.
Begin proving safety and effectiveness across red, blue, and purple states, kicking off the multi-year studies that anchor the strategy.
Begin proving safety and effectiveness across red, blue, and purple states, kicking off the multi-year studies that anchor the strategy.
Unlike most medications, psychedelic-assisted therapy (PAT) is an intensive, multi-component intervention: structured preparation sessions, guided medicine experiences, and weeks of integration support. The therapy's effectiveness depends on the full care model, not the medicine alone, creating a coverage challenge Medicaid has rarely faced. Pulling together the data state decision-makers will need is uniquely difficult, because the evidence has to speak to an ecosystem of care, not a single prescription. State Medicaid programs need evidence that:
Group-based care models can maintain clinical effectiveness while reducing per-participant cost to publicly sustainable levels.
Peer facilitators and community health workers, not only licensed clinicians, can safely deliver components of care.
Integration support meaningfully affects outcomes, and thus belongs in any covered benefit package.
The full care model works for Medicaid populations: people with PTSD, treatment-resistant depression, and substance use disorders who are disproportionately low-income, unhoused, and from communities of color.
PMHA's pilots are purpose-built to answer exactly these questions, producing the real-world, Medicaid-aligned evidence that turns a promising therapy into a covered, sustainable benefit.
Structured engagement ensures pilot models reflect the needs, experiences, and realities of the communities they aim to serve.
State and philanthropically supported group psilocybin therapy pilot for PTSD under SB 219, the nation's first medical psilocybin program. Generates the first real-world safety and feasibility data, integrated with wraparound and culturally responsive care models, including three months of Circle of Care integration support after the clinical protocol.
Larger-scale group-model pilot for treatment-resistant depression with access to robust claims data, with the Camden Coalition and Cooper University Health Care as implementation partners. Positioned to become a national infrastructure and technical-assistance hub for other states.
Tests model viability in a politically conservative environment, addressing the reality that Medicaid coverage decisions are made at the state level and states tend to follow politically similar peers. Co-design begins upon funding. Estimated at $2 million total, with $1.5 million sought in catalytic philanthropic capital to unlock the remaining state support.
Partners with one or more Certified Community Behavioral Health Clinics, an already-growing source of Medicaid behavioral health care, whose bundled-payment approach lends itself to the PAT care model. Tests integration into an existing bundled-payment structure designed for whole-person care, with model design alongside the Center for Health Care Strategies.
Synthesizes findings from Pilots 1 to 4 into a gold-standard outcomes and ROI study, aligning community providers, policymakers, and payers around the case for Medicaid reimbursement nationally.
PMHA Alliance does this work in deep partnership, bridging the psychedelic science, health equity, public-health, Medicaid policy, and community-based organization fields across our national strategy.
A new report with the Center for Health Care Strategies maps what state Medicaid programs need to prepare for psychedelic-assisted therapy, from evidence and reimbursement to provider readiness and equity.
Our response to HRSA's request for information lays out what it will take to build a trained workforce and care models that make psychedelic-assisted therapy accessible to people on Medicaid.
PMHA Alliance co-authors its first peer-reviewed article, describing the design of New Mexico's Group Psilocybin-Assisted Therapy (GPAT) study for PTSD and the community engagement process that shaped it.
A season of momentum: UNM's group psilocybin-assisted therapy study opens recruitment, our Circle of Care integration ecosystem is in development, and the New Jersey co-design phase with Camden Coalition gets underway, plus a partner spotlight on Denali Wilson.
Jeffrey Walker, a founding advisory member of PMHA Alliance, talks about how we got here and where we're going in the field of psychedelic-assisted mental health.
